SCHEMBL6412005

SCHEMBL6412005

Oc1cc(-c2cccs2)n[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.58
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
MAPT P10636 5/20 0.49
NFKB1 P19838 1/20 0.49
AHR P35869 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
HPGD P15428 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
ADORA3 P0DMS8 1/20 0.45
RAB9A P51151 2/20 0.45
GAA P10253 1/20 0.45
ALOX15 P16050 1/20 0.45
RPS6KB2 Q9UBS0 1/20 0.43
NPC1 O15118 2/20 0.42
POLB P06746 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414035 0.78 SMN1; SMN2 (0.58) SMN1; SMN2MEN1KMT2AMAPTNFKB1
SCHEMBL1143192 0.78 SMN1; SMN2 (0.58) SMN1; SMN2MEN1KMT2AMAPTNFKB1
SCHEMBL1761466 0.76 TP53 (0.58) SMN1; SMN2MEN1KMT2AALOX15
SCHEMBL4923288 0.75 SMN1; SMN2 (0.55) SMN1; SMN2MEN1KMT2AMAPTNFKB1
SCHEMBL2845171 0.75 PLA2G10 (0.57) SMN1; SMN2MEN1KMT2AMAPTNFKB1
SCHEMBL14400727 0.74 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2AMAPTNFKB1
SCHEMBL624712 0.74 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2AMAPTNFKB1
SCHEMBL5207573 0.74 SMN1; SMN2 (1.00) SMN1; SMN2MEN1KMT2AMAPTHPGD
SCHEMBL14373074 0.74 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2AMAPTNFKB1
SCHEMBL6417475 0.74 RAB9A (0.62) SMN1; SMN2MEN1KMT2AMAPTNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6593358-B1 Method for controlling pests, comprising the step of allowing a pesticidally effective amount of one or more compounds selected from the group consisting of one or more compounds of the formula (Ia) according to claim 2 and one or compounds NIHON BAYER AGROCHEM K.K. (JP) 2003-07-15 US claimed
EP-1200425-A1 THIENYL-PYRAZOLES AND THEIR USE FOR CONTROLLING PESTS NIHON BAYER AGROCHEM K.K. (JP) 2002-05-02 EP claimed
WO-2001005787-A1 THIENYL-PYRAZOLES AND THEIR USE FOR CONTROLLING PESTS NIHON BAYER AGROCHEM K.K. (DE) 2001-01-25 WO claimed
US-20050048092-A1 Thienyl-pyrazoles and their use for controlling pests WADA KATSUAKI (JP) 2005-03-03 US disclosed
US-6593358-B1 Method for controlling pests, comprising the step of allowing a pesticidally effective amount of one or more compounds selected from the group consisting of one or more compounds of the formula (Ia) according to claim 2 and one or compounds NIHON BAYER AGROCHEM K.K. (JP) 2003-07-15 US disclosed
EP-1200425-A1 THIENYL-PYRAZOLES AND THEIR USE FOR CONTROLLING PESTS NIHON BAYER AGROCHEM K.K. (JP) 2002-05-02 EP disclosed
WO-2001005787-A1 THIENYL-PYRAZOLES AND THEIR USE FOR CONTROLLING PESTS NIHON BAYER AGROCHEM K.K. (DE) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050048092-A1 Thienyl-pyrazoles and their use for controlling pests CBR3, C1S, CYP4B1 SMN1; SMN2 4328/4885MEN1 2046/4885KMT2A 3475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.